Artivion, Inc. $AORT Shares Sold by Juniper Investment Company LLC

Juniper Investment Company LLC cut its stake in Artivion, Inc. (NYSE:AORT) by 10.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,189,136 shares of the company’s stock after selling 144,556 shares during the period. Artivion accounts for approximately 18.6% of Juniper Investment Company LLC’s investment portfolio, making the stock its 2nd largest holding. Juniper Investment Company LLC owned 2.51% of Artivion worth $54,236,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Summit Partners Public Asset Management LLC bought a new position in shares of Artivion during the fourth quarter worth about $39,401,000. Champlain Investment Partners LLC acquired a new position in Artivion during the 3rd quarter valued at about $17,912,000. Goldman Sachs Group Inc. grew its position in Artivion by 144.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after purchasing an additional 317,518 shares during the last quarter. Two Sigma Investments LP grew its position in Artivion by 235.5% in the 3rd quarter. Two Sigma Investments LP now owns 446,535 shares of the company’s stock worth $18,906,000 after purchasing an additional 313,446 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Artivion by 8.3% in the third quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company’s stock valued at $128,250,000 after purchasing an additional 232,424 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Artivion Stock Performance

Shares of NYSE AORT opened at $21.27 on Thursday. Artivion, Inc. has a 1 year low of $19.16 and a 1 year high of $48.25. The firm has a market cap of $1.03 billion, a P/E ratio of 88.63 and a beta of 1.26. The stock has a fifty day moving average price of $28.16 and a two-hundred day moving average price of $36.44. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 3.86.

Insiders Place Their Bets

In related news, SVP Andrew M. Green sold 44,001 shares of Artivion stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the transaction, the senior vice president directly owned 60,259 shares of the company’s stock, valued at $1,247,361.30. The trade was a 42.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AORT shares. LADENBURG THALM/SH SH upgraded Artivion from a “neutral” rating to a “buy” rating and set a $42.00 price objective for the company in a research report on Friday, April 10th. Stifel Nicolaus set a $45.00 target price on Artivion in a research note on Monday, June 1st. Citizens Jmp reduced their price target on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. Canaccord Genuity Group reissued a “buy” rating and set a $36.00 price target on shares of Artivion in a report on Tuesday. Finally, Needham & Company LLC cut their price objective on shares of Artivion from $58.00 to $44.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $44.17.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.